Regencell Bioscience: The Story Behind a 46,000% Stock Surge
Imagine a company’s stock soaring by an incredible 46,000%. Yet, it hasn’t made a single penny in revenue. Sounds impossible, right? But that’s exactly what happened with Regencell Bioscience Holdings Limited, a biotech company focused on herbal medicine.
The Unbelievable Rise
Regencell’s shares skyrocketed by 46,000% in 2025. This is truly astonishing, especially since the company hasn’t generated any revenue since it was founded.
Key Points:
- Regencell started trading on the Nasdaq Capital Market in 2021.
- Despite minimal news from the company, its stock has seen a massive increase.
- The company is still in the research and development phase, with no revenue reported.
According to Bloomberg, Regencell went from being a penny stock in April to having a market value of about $30 billion. Just a year ago, its market capitalization was only $53 million.
About Regencell Bioscience Holdings
Regencell has kept its operations going through shareholder loans and money from its IPO. The IPO brought in $21.85 million, with an extra $2.85 million from additional shares.
What Does Regencell Do?
- The company is based in the Cayman Islands.
- It focuses on creating natural herb-based medicines for neurological conditions like ADHD and autism.
- Their products are based on traditional Chinese medicine (TCM) and contain only natural ingredients.
Regencell has not made any money from its TCM products. It also hasn’t applied for any regulatory approvals or patents. The company even stated in a filing that it might never be profitable.
COVID-19 Venture
In 2022, Regencell started working on COVID-19 treatments. They conducted clinical trials for a new treatment approach. The company reported that their treatment could reduce and eliminate COVID symptoms in six days. However, these findings still need to be reviewed by other experts.
Why the Huge Stock Fluctuations?
The big changes in Regencell’s stock price are due to its limited float. Out of about 500 million shares, only 30 million are available for trading. This is very different from companies like Apple and Tesla, where most shares are tradeable.
Most of Regencell’s shares are held by insiders. The CEO, Yat-Gai Au, controls 86% of the shares.
